Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-01-16
Target enrollment:
Participant gender:
Summary
RATIONALE: Cediranib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work
in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. It is not yet known whether cediranib is more effective than a
placebo when given together with paclitaxel and carboplatin in treating patients with
non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying how well cediranib works when given
together with paclitaxel and carboplatin in treating patients with stage IIIB or stage IV
non-small cell lung cancer.